Semaglutide Price Guide is an educational pricing and comparison resource operated by Premium Health Solutions. Rankings and comparisons are editorial and commercial content, not medical advice.

Pharmacology

Why semaglutide is titrated slowly

Starting low and stepping up over months is about tolerability, not just caution.

Reviewed 2026-06-04 Physician-reviewed How we research

Quick Answer

Injectable semaglutide typically starts at a non-therapeutic 0.25 mg weekly and increases about every 4 weeks toward a maintenance dose (up to 2.0 mg for Ozempic or 2.4 mg for Wegovy). Slow escalation lets the gut adapt and reduces nausea and other GI effects. The starting dose is for tolerance, not treatment. Compounded semaglutide is not FDA-approved.

Key Facts

  • Injectable usually starts at 0.25 mg weekly (a non-therapeutic 'introduction' dose)
  • Increases at intervals of about 4 weeks, matching time to steady state
  • Maintenance: up to 2.0 mg (Ozempic) or 2.4 mg (Wegovy)
  • Slow escalation reduces nausea, vomiting and other GI effects
  • Pace can be slowed or held if side effects are significant

The escalation schedule

For Wegovy, the labeled schedule steps through 0.25, 0.5, 1.0 and 1.7 mg before reaching the 2.4 mg maintenance dose, with about four weeks at each step. Ozempic escalates toward 1.0–2.0 mg. The four-week spacing matches the roughly four to five weeks needed to reach steady state at each dose.

Why start sub-therapeutic

The 0.25 mg starting dose is intended to build gastrointestinal tolerance, not to treat — it is below the doses that drive most of the glucose and weight effects. Introducing the drug gently reduces the intensity of nausea and other GI symptoms that are most likely when levels rise.

Pacing the increases

If side effects are significant at a step, a clinician may delay the next increase, hold a dose, or step back. There is no requirement to reach the maximum dose; the right maintenance dose is the lowest one that meets the goal with acceptable tolerability. Rushing tends to worsen side effects without improving long-term results.

Why this matters for cost

Because patients spend weeks at lower doses before maintenance, the price that matters long-term is the maintenance-dose price, not the intro. With flat-rate providers the cost is the same throughout; with tiered providers it can climb. Model your total with the cost calculator.

Frequently asked questions

Why does semaglutide start at 0.25 mg?

The 0.25 mg dose is a non-therapeutic introduction dose to build tolerance and limit nausea; it is increased after about four weeks.

Do you have to reach the maximum dose?

No. The maintenance dose is the lowest one that meets your goal with acceptable side effects; many people do well below the maximum.

References

  1. U.S. Food and Drug Administration. Wegovy, Ozempic and Rybelsus (semaglutide) prescribing information. Novo Nordisk.
  2. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
  3. Overgaard RV, et al. Clinical pharmacokinetics of semaglutide. Clin Pharmacokinet. 2019.

Citations are for educational reference; this article summarizes published research in plain language and is not medical advice.

Bottom Line

Semaglutide is titrated slowly so the gut can adapt, which limits nausea. The starting dose is for tolerance, not treatment, and there is no prize for escalating quickly.

Related from the Journal

Managing nausea

Reducing side effects.

Pharmacokinetics

Half-life and steady state.

Price by dose

How dosing affects cost.

Compounded semaglutide is not FDA-approved as a finished drug product. Compounded medications may be prescribed only when clinically appropriate and must be evaluated by a licensed prescriber. Branded medications such as Wegovy and Ozempic are FDA-approved products; compounded semaglutide is different and should not be described as FDA-approved, “generic Wegovy,” or “generic Ozempic.”
Compare NexLife plans